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Abstract
Background
Influence of tumor subtype, radiological sign and prognostic factors on tumor size
discrepancies between DBT and final histology has not been completely investigated so far.
Purpose
To study the influence of tumor subtype, radiological sign and prognostic factors on tumor size
discrepancies between digital breast tomosynthesis and final histology.
Material and methods
This is a retrospective study conducted between January 2015 and December 2016. After IRB
approval, 130 consecutive patients with breast cancer diagnosed with digital breast
tomosynthesis (DBT) were evaluated. A discrepancy between DBT and final histology was
considered present if the difference was above the cut-off of 5 mm. Tumor subtype, radiological
sign and prognostic factors were evaluated in patients with discrepancies. Descriptive statistic
and non-parametric tests were used.
Results
A total of 105 cases of cancer, in 96 patients, all female, were included. Mean age was 61 years
(range: 35-82 yrs). In 19 (18.1%) cases, discrepancies were found: 13 (68.4%) were
underestimated by DBT. For tumor subtype, 10 (52.6%) were infiltrating lobular carcinomas
(ILC) (p < 0.01). Fourteen (73.7%) discordant cases were architectural distortions (p < 0.01).
Prognostic factors did not affect tumor size discrepancies.
Conclusion
ILC or an architectural distortion represents the majority of cases of tumor size discrepancies
between DBT and final histology.
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Introduction
Accurate size prediction of an invasive breast cancer is important in preoperative planning, as a
prognostic indicator and consequently for patient management. With the increasing use of
breast-conserving surgery and neoadjuvant chemotherapy, the ability to correctly determine
maximum tumor extent non-invasively is essential. Under-estimating pre-surgical tumor size
may lead to incomplete margins and consequently to re-excision [1]. Although pathologic
measurement is regarded as the gold standard, important therapeutic decisions are made on the
basis of the tumor size assessment by physical examination and imaging, indeed the
pathological tumor staging could not be yet available [1-3].
There have been several attempts to predict breast tumor size based on medical imaging [1-5].
Preoperative tumor size is commonly measured on mammography and ultrasonography.
However, using mammography tumor measurements are affected by superimposition of
anatomical structures due to the 2D nature of mammography especially at the tumor
boundaries [3-5]. Ultrasound, on the other hand, is likely to underestimate the real tumor size
due to the overlap in the appearance among desmoplastic reaction and tumoral tissue [5].
Digital breast tomosynthesis, a pseudo-3D mammography, could overcome these limitations by
reducing the effect of tissue superimposition [1-5]. Digital breast tomosynthesis (DBT) is a
three-dimensional X-ray breast imaging method in which high spatial-resolution tomographic
images of the breast are reconstructed from multiple low-dose projection exposures acquired by
a digital detector from a mammographic X-ray source which moves over a limited angle. The
total mean glandular dose for a DBT examination is comparable to that of a two-view
mammographic examination, with a higher sensitivity for breast cancer detection [6,7]. DBT
and magnetic resonance imaging (MRI) are considered superior to digital mammography and
ultrasound (US) in the preoperative assessment of breast tumor size [1] and MRI overestimated
tumor size in ductal cancers and slightly underestimated it in lobular cancers [2]. Moreover,
DBT showed characteristic imaging features of breast cancers according to molecular
subtype [8], but the influence of tumor subtype, radiological sign and prognostic factors on
tumor size discrepancies between DBT and final histology has not been completely investigated
so far. Therefore, the purpose of this study is to evaluate the influence of tumor subtype,
radiological sign and prognostic factors on tumor size discrepancies between digital breast
tomosynthesis and final histology.
Materials And Methods
IRB approval was obtained and written informed consent was waived (Blinded). This is a
retrospective study, based on data already stored in the Hospital (Blinded) database. A total of
130 consecutive breast cancer patients (from January 2015 to December 2016) were included.
All cancers were visible at DBT and histologically confirmed (all lesions were classified
according to the BIRADS including 22 r4b, 24 r4c and 84 r5). Histology was considered suitable
for the study if derived from micro-histologic biopsy performed in this center. All cancers were
visible at DBT and histologically confirmed. Histology was considered suitable for the study if
derived from micro-histologic biopsy performed in this center. Patients operated outside of our
center and those cases of small clusters microcalcifications (less than 10 mm) studied by
vacuum-assisted breast biopsy (VABB) stereotactic or ultrasound-guided were excluded to
reduce biases related to patients selection and inaccuracy of measurements for very small
lesions. DBT (Hologic, Selenia Dimensions; Bedford, MA) was done with both a mediolateral-
oblique (MLO) views and cranio-caudal (CC) views. Two board-certified radiologists with breast
imaging experience of 20 and 12 years, respectively, participated in the study. Each reader was
blinded to the final results of imaging methods, any clinical information and pathological type
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of the cancer. Hologic SecurView workstations, optimized to read both 2D and 3D images, were
used for screen reading. The longest diameter measured on CC or MLO view was recorded for
statistical analysis; the measurements were made on the 3D images. DBT measurements were
considered concordant with histology if they were within ±5 mm, and under- and
overestimated, respectively, if they were <5 mm and >5 mm compared to pathological size
according to recent literature [1]. In the case of multifocal lesions, it was decided not to
consider the extremes of the overall area involved, but to measure each lesion, for the purpose
of a more precise evaluation.
Biopsy procedures
Core-needle biopsy (CB) was done for mass lesions, VABB in cases of micro-calcifications,
distortions and asymmetric density. In patients with clusters of microcalcifications,
radiographs of biopsy specimens were acquired to document the harvest obtained by means of
VABB or CB. Interventional procedures were performed as suggested by recent guidelines [9].
Ultrasound was performed by means of a high-frequency linear-array transducer of 13 MHz. In
our unit, an automatic spring-loaded 14G biopsy-needle with a 2/10 mm penetration depth
(Tsunami Medical, Modena, Italy) was used to obtain from three to five cylinder-shaped
samples of tissue from the suspicious area.
Vacuum-assisted breast biopsy
All VABB procedures were performed with ATEC (Automatic Tissue Extraction and Collection)
stereotactic-guided breast biopsy system (Hologic, Indianapolis, IN, USA). Twelve cores were
taken on a 360° rotation of the biopsy device and a 9G needle allowed to remove the lesion in a
piecemeal fashion through a 2-3 mm skin incision. At the end of sampling, the operator
inserted a Stereotactic and MR-compatible clip (Atec TriMark, titanium biopsy site marker;
Hologic).
Pathological analysis
Tumor size was assessed by gross tumor and microscopic examination of the excised tumor
specimens by one breast pathologist with 22 years of experience in breast pathology. Tumors
were classified according to five histological subgroups, including invasive ductal carcinoma
(IDC), invasive lobular carcinoma (ILC), ductal carcinoma in situ (DCIS), mixed IDC/ILC and
other histological types (mucinous, papillary, medullary, tubular, and apocrine breast
carcinoma). According to the common practice of the pathology service of our institution, all
surgical specimens were cut into 5-mm thick levels along their longest axis (i.e., 5-mm slicing
technique). The measurements were then calculated by multiplying number of levels showing
cancer by the thickness of each level. When measuring lesion size only the largest diameter
(expressed in mm) was considered. In the case of multifocal disease, the final pathology size
was obtained by summing the greater microscopic dimension of different tumor foci within the
same breast quadrant.
Standard prognostic factors were reported: grading (G), estrogen receptor (ER) and
progesterone receptor (PR) status, HER2 expression, Ki-67 proliferation.
Statistical analysis
Summary statistics were reported for all categorical variables. Mean ± standard deviation and
ranges were reported for numeric variables. Concordance between DBT size and
histopathologic size was assessed considering a cut-off rate of >5 mm for discrepant cases.
Comparisons between concordant and discrepant cases were thus performed using Pearson
Chi-square of independence test or Fisher’s exact test, as appropriate. Multivariate analysis was
used to study prognostic factors in concordant and discordant cases.
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Results
After the exclusion criteria, our series included 105 cases of cancer, in 96 patients, all female
(mean age: 61 years; age range: 35-82 years).
According to radiological findings on DBT there were 37 nodules (35.2%), 47 distortions
(44.8%) and 21 clusters of microcalcifications (20%). According to histology, 66 cases (62.8%)
were infiltrating ductal carcinoma, 14 cases (13.3%) were found to be DCIS, (IDC), 14 cases
(13.3%) infiltrating lobular carcinoma (ILC), and two cases (1.9%) mixed carcinomas type duct-
lobular and finally nine cases (8.6%) rare histological types. The average diameter of the lesions
at histology was 16.4 mm ± 14.2 mm. Among the most frequent lesions encountered in the
study, ductal carcinomas in situ presented in tomosynthesis had an average diameter of 32
mm, infiltrating ductal carcinomas had an average diameter of 13.5 mm, while for infiltrating
lobules they had an average diameter of 17 mm.
Significant differences (>5 mm) between DBT measurement and tumor size at the pathology
were present in 19/105 cases (18.1%). DBT underestimated lesion size in 13/19 (68.4%) cases
and overestimated in 6/19 (31.6%). Among these 19 neoplastic lesions, the most frequent
correspondent radiologic finding at DBT was architectural distortions (n = 14/19; 73.7%). The
most represented histological type was infiltrating lobular type ILC (n = 10/19, 52.6%), this data
was statistically significant at Pearson’s Chi-square (p < .001). The number of discrepancies
according to histology is reported in Table 1 and Table 2.






TABLE 1: Number and percentage of discrepancies according to histology regardless
under- or over-estimation.
IDC: Invasive ductal carcinoma; DCIS: Ductal carcinoma in situ; ILC: Invasive lobular carcinoma.
2019 Garlaschi et al. Cureus 11(10): e6046. DOI 10.7759/cureus.6046 4 of 8
 DCIS IDC ILC Mixed carcinomas Rare histologies
Underestimation 0 3 8 0 2
Concordance* 14 60 4 1 7
Overestimation 0 3 2 1 0
Total 14 66 14 2 9
TABLE 2: Number of discrepancies according to histology.
*Concordance: tumor size discrepancy between digital breast tomosynthesis (DBT) and histology ≤5 mm
IDC: Invasive ductal carcinoma; DCIS: Ductal carcinoma in situ; ILC: Invasive lobular carcinoma.
Number of discrepancies according to radiological sign are reported in Table 3.
 Architectural distortions Masses Microcalcifications
Underestimation 8 4 1
Concordance* 33 33 20
Overestimation 6 0 0
Total 47 37 21
TABLE 3: Number of discrepancies according to radiological sign.
*Concordance: tumor size discrepancy between digital breast tomosynthesis (DBT) and histology ≤5 mm.
Comparing the overall distribution of tumor grading among cases without measurement
discrepancies (G1 n = 21 (20.0%); G2 n = 71 (67.6%); G3, n = 13 (12.4%)) and the grading
distribution among tumors with under- or overstimated size (G1 n = 5 (26.3%), G2 n = 12
(63.2%), and G3 n = 2 (10.5%)) there were no significant differences (p < 0.05). Similarly, there
were no significant differences (p < 0.05) for estrogen receptor (ER) and progesterone receptor
(PR) status, HER2 expression, Ki-67 proliferation.
Discussion
Accurate measurement of tumor extent is important for tumor staging, which in turn is an
important parameter making decision on treatment [3]. Recent literature strongly suggests that
DBT is superior to digital mammography for breast cancer detection; therefore DBT usage is
increasing in clinical practice in screening and diagnostic settings [10-16]. By consequence,
breast cancer measurements will likely frequently occur directly on DBT. For this reason, in this
study, we evaluated the influence of tumor subtype, radiological sign and prognostic factors on
tumor size discrepancies between digital breast tomosynthesis and final histology. The results
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of this study found that the majority of cases of tumor size discrepancies between DBT and
final histology are recorded when the tumor is an ILC at final histology or when the radiological
sign is an architectural distortion at DBT. Indeed, in 19 cancers with size discrepancies,
10 (52.6%) were infiltrating lobular carcinomas (ILC) and 14 (73.7%) discordant cases were
architectural distortions on DBT. In addition, DBT resulted to underestimate cancer size in the
majority of cases (n = 13/19, 68.4%). When compared with the data available in the literature,
the percentage of discrepancy between tomosynthesis and histology, using a predetermined 5-
mm cut-off, resulted to be between 10%-20% [1]. The relatively large number of architectural
distortions that determined tumor size discrepancies could be interpreted as the difficulty in
correct measuring a cancer presenting as a distortions in DBT. Indeed, despite the attempt to
estimate only the core of the lesion excluding as much as possible the spicules, lesion borders
probably remained unclear. Moreover, although it is shown that even for invasive lobular
carcinomas, the sensitivity of the DBT is greater than that of digital mammograpy [17], this
study suggests a reduced reliability in correctly defining the actual size of the tumor. Our
results are concordant with a recent study in which DBT failed to accurately assess tumor size
of ILC and concordance in tumor size measurement between DBT and pathology was fair
(intraclass correlation coefficient = 0.24) [17]. It is possible that the coexistence of infiltrating
lobular carcinoma at histology and architectural parenchimal distortion at imaging finding
represent the combination with greater risk of discrepancies in the exact definition of tumor
size. Indeed, invasive lobular carcinoma (ILC) is the most common “special” type of breast
cancer (approximately 5-15% of all breast cancers) with a characteristic grow pattern involving
the infiltration of single cells or single files of cells through the stroma, with little alterations
of normal tissue architecture and relative preservation of normal breast parenchymal
architecture [18]. The complex biology of ILC is probably one of the possible explanations of
tumor size discrepancies among DBT and final histology. This data regarding DBT
measurements could be considered consistent with the recent observation on MRI that tumor
type and poorly defined margins are independent factor for imaging-pathology discordance in
lesion sizing [19].
Regarding common prognostic factors, no significant differences were found among patients
with concordance and discrepancies among DBT and final histology for grading, estrogen
receptor and progesterone receptor, HER2 expression and Ki-67 proliferation. This data could
suggest that common prognostic factors do not influence the rate of disagreement between
DBT and pathology examination for tumor size estimation. However, it is possible that more
complex analysis on prognostic factors such as those based on radiomics will find some
prognostic features linked to tumor size discrepancies [20-22].
This study has several limitations. The first is the retrospective nature, the second is that we
have not considered other diagnostic tools potentially more sensitive than tomosynthesis, such
as the MRI. However, DBT usage is likely to become largely adopted in screening and diagnostic
setting whereas MRI is limited to specific indications. In addition, the sample of women
included in the study could be considered not so large to detect small differences especially
regarding prognostic factors. However the sample size was deemed to be sufficient to detect
differences if clinically relevant. Moreover, the number of patients was not sufficient to
compare rare tumoral subtypes, but the data of this study could be included in future meta-
analyses. Finally, we did not evaluate advanced imaging features to be correlated with common
prognostic factors. Indeed, it has been shown that some radiomic features can be
distinguishing between ER+ versus ER−, PR+ versus PR−, HER2+ versus HER2−, and triple-
negative adding new insights into breast cancer imaging [21]. Further studies are needed to
assess if some radiomic features with potential prognostic value could influence tumor size
discrepancies among imaging techniques and final histology.
Conclusions
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DBT showed characteristic imaging features of breast cancers according to molecular subtype,
however, the influence of tumor subtype, radiological sign and prognostic factors on tumor size
discrepancies between DBT and final histology has not been completely investigated so far and
we evaluated the influence of tumor subtype, radiological sign and prognostic factors on tumor
size discrepancies between DBT and final histology on 105 cases of cancer in 96 patients. This
study found that tumor size discrepancies between DBT and final histology are mainly due to
the diagnosis of ILC at histology or to an architectural distortion seen on DBT. Common
prognostic factors did not affect tumor size discrepancies.
Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study. IRB approval was
obtained and written informed consent was waived issued approval 263REG2017. IRB approval
was obtained and written informed consent was waived (263REG2017). This is a retrospective
study, based on data already stored in the Hospital database. Animal subjects: All authors
have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest:
In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Payment/services info: All authors have declared that no financial support was received from
any organization for the submitted work. Financial relationships: All authors have declared
that they have no financial relationships at present or within the previous three years with any
organizations that might have an interest in the submitted work. Other relationships: All
authors have declared that there are no other relationships or activities that could appear to
have influenced the submitted work.
References
1. Luparia A, Mariscotti G, Durando M, et al.: Accuracy of tumour size assessment in the
preoperative staging of breast cancer: comparison of digital mammography, tomosynthesis,
ultrasound and MRI. Radiol Med. 2013, 118:1119-1136. 10.1007/s11547-013-0941-z
2. Leddy R, Irshad A, Metcalfe A, Mabalam P, Abid A, Ackerman S, Lewis M: Comparative
accuracy of preoperative tumor size assessment on mammography, sonography, and MRI: is
the accuracy affected by breast density or cancer subtype?. J Clin Ultrasound. 2016, 44:17-25.
10.1002/jcu.22290
3. Dummin LJ, Cox M, Plant L: Prediction of breast tumor size by mammography and
sonography--A breast screen experience. Breast. 2007, 16:38-46. 10.1016/j.breast.2006.04.003
4. Wasif N, Garreau J, Terando A, Kirsch D, Mund DF, Giuliano AE: MRI versus ultrasonography
and mammography for preoperative assessment of breast cancer. Am Surg. 2009, 75:970-975.
5. Förnvik D, Zackrisson S, Ljungberg O, Svahn T, Timberg P, Tingberg A, Andersson I: Breast
tomosynthesis: accuracy of tumor measurement compared with digital mammography and
ultrasonography. Acta Radiol. 2010, 51:240-247. 10.3109/02841850903524447
6. Endo T, Morita T, Oiwa M, et al.: Diagnostic performance of digital breast tomosynthesis and
full-field digital mammography with new reconstruction and new processing for dose
reduction. Breast Cancer. 2018, 25:159-166. 10.1007/s12282-017-0805-9
7. Mariscotti G, Durando M, Houssami N, et al.: Comparison of synthetic mammography,
reconstructed from digital breast tomosynthesis, and digital mammography: evaluation of
lesion conspicuity and BI-RADS assessment categories. Breast Cancer Res Treat. 2017,
166:765-773. 10.1007/s10549-017-4458-3
8. Lee SH, Chang JM, Shin SU, Chu AJ, Yi A, Cho N, Moon WK: Imaging features of breast
cancers on digital breast tomosynthesis according to molecular subtype: association with
breast cancer detection. British J Radiol. 2017, 27:20170470. 10.1259/bjr.20170470
9. van Dongen JA, Bartelink H, Fentiman IS, et al.: Factors influencing local relapse and survival
and results of salvage treatment after breast-conserving therapy in operable breast cancer:
EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II
breast cancer. Eur J Cancer. 1992, 28A:801-805. 10.1016/0959-8049(92)90118-l
10. Houssami N, Lång K, Bernardi D, Tagliafico A, Zackrisson S, Skaane P: Digital breast
2019 Garlaschi et al. Cureus 11(10): e6046. DOI 10.7759/cureus.6046 7 of 8
tomosynthesis (3D-mammography) screening: a pictorial review of screen-detected cancers
and false recalls attributed to tomosynthesis in prospective screening trials. Breast. 2016,
26:119-134. 10.1016/j.breast.2016.01.007
11. Bernardi D, Belli P, Benelli E, et al.: Digital breast tomosynthesis (DBT): recommendations
from the Italian College of Breast Radiologists (ICBR) by the Italian Society of Medical
Radiology (SIRM) and the Italian Group for Mammography Screening (GISMa). Radiol Med.
2017, 122:723-730. 10.1007/s11547-017-0769-z
12. Bernardi D, Macaskill P, Pellegrini M, et al.: Breast cancer screening with tomosynthesis (3D
mammography) with acquired or synthetic 2D mammography compared with 2D
mammography alone (STORM- 2): a population-based prospective study. Lancet Oncol. 2016,
17:1105-1113. 10.1016/S1470-2045(16)30101-2
13. Tagliafico A, Houssami N, Calabrese M: Digital Breast Tomosynthesis: A Practical Approach .
Springer International Publishing, 2016. 10.1007/978-3-319-28631-0
14. Tagliafico AS, Mariscotti G, Valdora F, et al.: A prospective comparative trial of adjunct
screening with tomosynthesis or ultrasound in women with mammography-negative dense
breasts (ASTOUND-2). Eur J Cancer. 2018, 104:39-46. 10.1016/j.ejca.2018.08.029
15. Tagliafico AS, Calabrese M, Bignotti B, et al.: Accuracy and reading time for six strategies
using digital breast tomosynthesis in women with mammographically negative dense breasts.
Eur Radiol. 2017, 27:5179-5184. 10.1007/s00330-017-4918-5
16. Gilbert FJ, Tucker L, Gillan MG, et al.: TOMMY trial: a comparison of TOMosynthesis with
digital MammographY in the UK NHS Breast Screening Programme. Health Technol Assess.
2015, 19:1-136. 10.3310/hta19040
17. Chamming’s F, Kao E, Aldis A, Ferré R, Omeroglu A, Reinhold C, Mesurolle B: Imaging
features and conspicuity of invasive lobular carcinomas on digital breast tomosynthesis.
British J Radiol. 2017, 90:20170128. 10.1259/bjr.20170128
18. Oliveira TMG, Elias J, Melo AF, et al.: Evolving concepts in breast lobular neoplasia and
invasive lobular carcinoma, and their impact on imaging methods. Insights Imaging. 2014,
5:183-194. 10.1007/s13244-014-0324-6
19. Mennella S, Garlaschi A, Paparo F, et al.: Magnetic resonance imaging of breast cancer: factors
affecting the accuracy of preoperative lesion sizing. Acta Radiol. 2015, 56:260-268.
10.1177/0284185114524089
20. Gillies RJ, Kinahan PE, Hricak H: Radiomics: images are more than pictures, they are data .
Radiology. 2016, 20:563-577. 10.1148/radiol.2015151169
21. Tagliafico AS, Valdora F, Mariscotti G, et al.: An exploratory radiomics analysis on digital
breast tomosynthesis in women with mammographically negative dense breasts. Breast. 2018,
40:92-96. 10.1016/j.breast.2018.04.016
22. Limkin EJ, Sun R, Dercle L, et al.: Promises and challenges for the implementation of
computational medical imaging (radiomics) in oncology. Ann Oncol. 2017, 28:1191-1206.
10.1093/annonc/mdx034
2019 Garlaschi et al. Cureus 11(10): e6046. DOI 10.7759/cureus.6046 8 of 8
